Chemically modified RNAs and 3D printing in bone regenerative therapy
The ultimate goal of this EU-funded cmRNAbone project is to develop reliable bone regenerative technology to treat widespread bone traumatic injuries and osteoporosis-induced bone fragile fractures. Researchers aim to create a novel bone regenerative therapeutic approach using a combination of chemically modified RNAs and 3D printing technologies. Chemically modified RNAs of the growth factors targeting neurogenesis, vasculogenesis and osteogenesis will be synthesised together with vectors based on lipids and polysaccharide nanocapsules for the RNAs' delivery. Delivery of the vectors will be achieved with a 3D bioprinting process using hyaluronan-calcium phosphate biomaterial ink that can be loaded with vectors and able to be released later. This bio-ink will provide osteoinductivity and laminin-derived peptides for guiding sensory neurons and endothelial cells' ingrowth. The project aims to achieve preclinical proof of concept for selected drug candidates and prepare a first-in-human clinical trial.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action